At-Risk Launches: Neurontin Settlement Leaves Question Of Jury Damage Calculations Unresolved
This article was originally published in The Pink Sheet Daily
Teva and Actavis settle with Pfizer two weeks into a jury trial to determine liability and damages for launching generic gabapentin at-risk.
You may also be interested in...
How risky are at-risk launches of generic products?
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.